Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to report sales of $2.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Spero Therapeutics posted sales of $5.15 million during the […]